Mastery EAQ Ch. 34

A  Strong contractions

B  Midline fundus

C  Decreased pain

D  Softened cervix

A  Pulmonary embolism

B  Ovarian failure

C  Abnormal vaginal bleeding

D  Renal failure

A  Anxiety, Dizziness, Blurred vision

B  Hirsutism, Dizziness,, Increased diuresis

C  Hirsutism, Bradycardia, Increased diuresis

D  Blurred vision, Bradycardia, Increased diuresis

A  For at least 1 month after starting the antibiotic

B  For at least 6 weeks, starting at the end of the antibiotic regimen

C  Until three throat cultures have been negative for the pathogen

D  During the entire period the patient is taking the antibiotic

A  Estradiol

B  Alendronate

C  Methylergonovine

D  Megestrol

A  Calcium gluconate

B  Epinephrine

C  Atropine

D  Protamine sulfate

A  Decrease the drug dose immediately.

B  Obtain a prescription for terbutaline.

C  Obtain a prescription for indomethacin.

D  Request a prescription to give calcium gluconate.

A  Place the patient on her left side.

B  Instruct the patient to bear down and push.

C  Administer phentolamine mesylate.

D  Immediately discontinue intravenous (IV) fluids.

A  Administer it before placenta delivery. Monitor blood pressure during administration. Assess for pelvic inflammatory disease. Question the prescription if the patient has liver disease.

B  Monitor the patient for blurred vision. Monitor blood pressure during administration. Assess for pelvic inflammatory disease. Question the prescription if the patient has liver disease.

C  Monitor the patient for blurred vision. Administer it before placenta delivery. Assess for pelvic inflammatory disease. Question the prescription if the patient has liver disease.

D  Monitor the patient for blurred vision. Monitor blood pressure during administration. Administer it before placenta delivery. Question the prescription if the patient has liver disease.

A  Uterine atony

B  Nausea and vomiting

C  Hypertension

D  Pelvic inflammatory disease

A  Blood pressure

B  Uterine contractions

C  Blood glucose

D  Temperature

A  Absence of cervical ripening at 42 weeks’ gestation

B  Vaginal bleeding at 38 weeks’ gestation

C  Ineffective contractions in a full-term pregnancy

D  Radiographic confirmation of cephalopelvic disproportion

A  Use of herbal supplements

B  Current tricyclic antidepressant use

C  Cigarette use

D  Low fluid intake

A  Fetal movement, Uterine hyperactivity, Complete blood cell count

B  The patient’s blood pressure and pulse, Complete blood cell count, Uterine hyperactivity

C  Fetal heart rate, Fetal movement, The patient’s blood pressure and pulse

D  Uterine hyperactivity, Fetal heart rate, Complete blood cell count

A  Denosumab

B  Ibandronate

C  Tamoxifen

D  Calcitonin

A  Inform the patient about the benefits and risks of the therapy.

B  Ask the patient to include soy in her diet.

C  Persuade the patient to start the therapy.

D  Advise the patient to engage in quiet activities.

A  “You may need to stop smoking during the therapy.”

B  “The treatment is likely to cause endometrial cancer.”

C  “The therapy may cause thromboembolic events.”

D  “The treatment should be started as soon as possible.”

A  Magnesium sulfate

B  Bed rest and hydration

C  Ritodrine

D  Terbutaline

A  Antibiotic therapy

B  Hypertension

C  Anticonvulsant therapy

D  Diabetes

A  Norethindrone and ethinyl estradiol

B  Medroxyprogesterone

C  Cervical cap with spermicidal jelly

D  Male condom with spermicidal jelly

A  Allergy to salmon

B  Current smoker

C  Breast cancer

D  Joint pain

A  “Space the medications 1 to 2 hours apart.”

B  “Discontinue the calcium supplement.”

C  “Obtain a prescription for increasing the bisphosphonate dose.”

D  “Replace the bisphosphonate with calcitonin.”

A  “Have tests for serum cholesterol.”

B  “Report missed menstrual periods.”

C  “Have a yearly mammogram.”

D  “Perform weight-bearing exercise.”

A  “Decreased Gn-RH suppresses the release of follicle-stimulating hormone.”

B  “High progesterone levels inhibit the release of luteinizing hormone.”

C  “Estrogen levels inhibit the release of follicle-stimulating hormone.”

D  “Surges of Gn-RH, follicle-stimulating hormone, and luteinizing hormone stimulate ovulation.”

A  “I no longer experience hot flashes.”

B  “I have not experienced any uterine bleeding.”

C  “I am no longer experiencing painful intercourse.”

D  “I have seen a great improvement in my sexual desire.”

A  Levothyroxine

B  Amoxicillin

C  Ferritin

D  Metformin

A  Contains estrogen, which stimulates bone reabsorption

B  Promotes bone absorption of calcium

C  Stimulates estrogen receptors on the bone to increase bone density

D  Inhibits osteoclast-mediated bone reabsorption

A  Atenolol, Levothyroxine

B  Warfarin, Cholestyramine

C  Multivitamin, Atenolol

D  Levothyroxine, Multivitamin

A  “I will take the medication on an empty stomach and not lie down for 30 minutes.”

B  “I need to take this medication with food to prevent damage to my esophagus.”

C  “I need to decrease my intake of dairy products to prevent hypercalcemia.”

D  “This medication will help relieve the bone pain I have from my osteoporosis.”

A  Chest pain, Hot flashes, Loss of appetite

B  Vertigo, Joint pain, Chest pain

C  Hot flashes, Loss of appetite, Joint pain

D  Hot flashes, Vertigo, Loss of appetite

A  To treat gestational hypertension

B  To terminate pregnancy

C  To treat pelvic inflammatory disease

D  To induce cervical ripening

A  Consumption of saturated fats

B  Smoking heavily every day

C  Increased body mass index (BMI)

D  Sedentary lifestyle

A  Estrogen monotherapy increases the risk of breast cancer.

B  Monotherapy with a progestin increases breast cancer risk.

C  Estradiol with progestin increases the risk of endometrial cancer.

D  Unopposed estrogen increases the risk of endometrial cancer.

A  Prostaglandin E

B  Clomiphene

C  Terbutaline

D  Oxytocin

A  Megestrol

B  Estrone

C  Estropipate

D  Medroxyprogesterone

A  Yellow undertone to the skin

B  Loss of hair

C  Hot flashes

D  Brown discoloration of face

A  Suggest the patient take aluminum hydroxide with the medication.

B  Monitor the patient’s blood pressure frequently.

C  Administer acetaminophen as needed.

D  Assess pulse oximetry continuously.

A  Dinoprostone

B  Clomiphene

C  Oxytocin

D  Indomethacin

A  Choriogonadotropin alfa

B  Ethinyl estradiol

C  Progesterone

D  Clomiphene

A  Uterine bleeding

B  Dysmenorrhea

C  Weight loss

D  Deep vein thrombosis

A  “The progestin in the regimen will help prevent ovarian cancer.”

B  “Endometrial cancer risk can be reduced by adding progestin.”

C  “The progestin in the regimen will help prevent breast cancer.”

D  “Vaginal cancer is prevented by adding progestin to the regimen.”

A  Elevated progesterone levels inhibiting the release of the luteinizing hormone

B  Interference with the proliferation of the fertilized ovum

C  Diminished endometrial tissue proliferation

D  Inhibition of the release of gonadotropins

A  Follicle-stimulating hormone

B  Luteinizing hormone

C  Antidiuretic hormone

D  Adrenocorticotropic hormone

A  Hypertension

B  Thrombophlebitis

C  Dysmenorrhea

D  Weight gain

A  Higher-pitched voice

B  Weight loss

C  Dry skin

D  Nausea

A  Termination of pregnancy

B  Accelerated labor

C  Postpartum hemorrhage

D  Premature labor

A  Alendronate

B  Medroxyprogesterone

C  Megestrol

D  Esterified estrogens

A  Phase 2

B  Phase 3

C  Phase 1

D  Phase 4

A  Biphasic

B  Triphasic

C  Monophasic

D  Extended-cycle

A  Follicle-stimulating hormone (FSH)

B  Luteinizing hormone (LH)

C  Luteotropic hormone

D  Interstitial cell-stimulating hormone

A  Indomethacin

B  Medroxyprogesterone acetate

C  Megestrol

D  Methylergonovine

A  Terbutaline

B  Magnesium sulfate

C  Methylergonovine

D  Oxytocin

A  Megestrol

B  Clomiphene

C  Methylergonovine

D  Raloxifene

A  Day 14

B  Day 3

C  Day 7

D  Day 21

A  Luteinizing hormone (LH)

B  Adrenocorticotropic hormone

C  Follicle-stimulating hormone (FSH)

D  Antidiuretic hormone

A  The patient is ready for delivery.

B  The patient’s blood pressure is stable.

C  The fetal heart rate is stable.

D  The contractions can be fatal to the patient.

A  Presence of abnormal uterine bleeding

B  Current smoking status

C  Current use of medications for depression

D  Compliance with the fertility drugs

A  Dementia, Breast cancer, Cigarette smoking, Cardiovascular disease, Serious cardiovascular events

B  Dementia, Breast cancer, Cigarette smoking, Cardiovascular disease, Ovarian cancer

C  Dementia, Ovarian cancer, Cigarette smoking, Cardiovascular disease, Serious cardiovascular events

D  Dementia, Breast cancer, Ovarian cancer, Cardiovascular disease, Serious cardiovascular events